Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

(2019) Ignace Vergote et al.   GYNECOLOGIC ONCOLOGY

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization

(2018) Yiu To Yeung et al.   EBioMedicine

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer

(2016) Xin Jin et al.   CANCER BIOLOGY & THERAPY

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

(2014) L Kristin Newby et al.   LANCET

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

(2013) R. M. Campbell et al.   MOLECULAR CANCER THERAPEUTICS

Temozolomide-related idiosyncratic and other uncommon toxicities

(2012) Sanjay Dixit et al.   ANTI-CANCER DRUGS

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients

(2012) K.L. McDonald et al.   EUROPEAN JOURNAL OF CANCER

O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions

(2012) Claire Villalva et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Primary brain tumours in adults

(2012) Damien Ricard et al.   LANCET

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

(2012) L Sokol et al.   LEUKEMIA

High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era

(2012) Chirag G. Patil et al.   NEURO-ONCOLOGY

Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system

(2012) G. Sarganas et al.   NEURO-ONCOLOGY

Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial

(2011) Jaime Gállego Pérez-Larraya et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation

(2011) Marcus Niewald et al.   Radiation Oncology

Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma

(2010) Jing Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatic encephalopathy after treatment with temozolomide

(2010) Annemarie Goldbecker et al.   JOURNAL OF NEURO-ONCOLOGY

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY